Mirae Asset Global Investments Co. Ltd. Buys New Shares in Pfizer Inc. $PFE

Mirae Asset Global Investments Co. Ltd. acquired a new stake in Pfizer Inc. (NYSE:PFE) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,721,270 shares of the biopharmaceutical company’s stock, valued at approximately $49,091,000.

A number of other large investors also recently bought and sold shares of PFE. BlackRock Inc. boosted its holdings in Pfizer by 6.3% in the second quarter. BlackRock Inc. now owns 529,670,433 shares of the biopharmaceutical company’s stock valued at $12,754,464,000 after acquiring an additional 31,412,883 shares during the last quarter. State Street Corp boosted its holdings in Pfizer by 1.8% in the 2nd quarter. State Street Corp now owns 307,090,897 shares of the biopharmaceutical company’s stock worth $7,394,749,000 after acquiring an additional 5,501,032 shares during the period. Bank of New York Mellon Corp increased its stake in Pfizer by 11.1% during the 1st quarter. Bank of New York Mellon Corp now owns 53,879,900 shares of the biopharmaceutical company’s stock worth $1,512,948,000 after buying an additional 5,364,929 shares during the period. Bank of America Corp DE acquired a new stake in shares of Pfizer during the second quarter valued at about $1,049,602,000. Finally, Dimensional Fund Advisors LP increased its position in shares of Pfizer by 0.8% during the first quarter. Dimensional Fund Advisors LP now owns 36,422,799 shares of the biopharmaceutical company’s stock worth $1,022,606,000 after acquiring an additional 293,029 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer reported that its Phase 3 MagnetisMM-32 trial of ELREXFIO met its primary endpoint in patients with relapsed or refractory multiple myeloma. The result supports another potential growth driver for Pfizer’s oncology portfolio. The FDA also expanded the use of TALZENNA plus XTANDI for certain men with metastatic hormone-sensitive prostate cancer, increasing the commercial opportunity for the combination. Pfizer cancer trial and FDA approval article
• Positive Sentiment: New real-world data from China showed continued momentum for lorlatinib in lung cancer treatment, potentially reinforcing the drug’s adoption and durability outside clinical-trial settings. Lorlatinib China study article
• Positive Sentiment: Pfizer launched a Phase 1 trial for Alzheimer’s candidate PF-08161842, adding a new early-stage asset to its pipeline. Although the program is years from potential commercialization, it gives investors another source of long-term optionality. PF-08161842 Alzheimer’s trial article
• Neutral Sentiment: Investors are focused on Pfizer’s third-quarter earnings report, scheduled for November 3. Attention will center on whether non-COVID products and pipeline progress can offset continuing declines in pandemic-related revenue. Pfizer Q3 earnings outlook article
• Negative Sentiment: Analysts remain cautious ahead of earnings, while commentary highlights that Pfizer’s nearly 6% dividend yield exceeded free cash flow in the prior year. That raises questions about long-term payout coverage, even though the dividend remains attractive to income-focused investors. Pfizer dividend safety article

Pfizer Trading Down 0.1%

Shares of PFE opened at $30.48 on Monday. Pfizer Inc. has a 1-year low of $23.62 and a 1-year high of $30.67. The business’s 50-day moving average price is $28.55 and its 200 day moving average price is $26.79. The company has a current ratio of 1.27, a quick ratio of 0.96 and a debt-to-equity ratio of 0.71. The stock has a market capitalization of $173.73 billion, a P/E ratio of 40.11, a P/E/G ratio of 2.07 and a beta of 0.31.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.68 by $0.09. Pfizer had a net margin of 6.80% and a return on equity of 19.63%. The company had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. During the same quarter last year, the business posted $0.78 EPS. The company’s revenue for the quarter was up 2.6% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 7th. Shareholders of record on Friday, November 6th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 5.6%. The ex-dividend date of this dividend is Friday, November 6th. Pfizer’s payout ratio is presently 226.32%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the company. Weiss Ratings raised Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Monday, August 31st. Cantor Fitzgerald increased their price objective on shares of Pfizer from $27.00 to $28.00 and gave the company a “neutral” rating in a research note on Thursday, October 8th. HSBC upped their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a “hold” rating in a research note on Thursday, September 10th. Wall Street Zen cut shares of Pfizer from a “buy” rating to a “hold” rating in a report on Saturday, October 10th. Finally, JPMorgan Chase & Co. increased their price target on Pfizer from $28.00 to $30.00 and gave the stock a “neutral” rating in a research report on Friday, October 9th. Five investment analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $28.65.

Pfizer Profile

Pfizer Inc is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research activities span areas including oncology, internal medicine, inflammation and immunology, hospital care, infectious diseases and rare diseases.

The company’s portfolio includes medicines such as Eliquis, Ibrance, Prevnar and Vyndaqel, as well as vaccines including Comirnaty, Abrysvo and Prevnar. Pfizer also develops treatments through internal research, licensing agreements and collaborations with other pharmaceutical and biotechnology companies.

Founded in Brooklyn, New York, in 1849 by Charles Pfizer and Charles Erhart, Pfizer has grown into an international healthcare company serving patients and healthcare providers in markets around the world.